Bruker Corporation

NasdaqGS:BRKR Stock Report

Market Cap: US$8.1b

Bruker Future Growth

Future criteria checks 3/6

Bruker is forecast to grow earnings and revenue by 108.3% and 4.8% per annum respectively. EPS is expected to grow by 108% per annum. Return on equity is forecast to be 16.3% in 3 years.

Key information

108.3%

Earnings growth rate

108.05%

EPS growth rate

Life Sciences earnings growth18.9%
Revenue growth rate4.8%
Future return on equity16.27%
Analyst coverage

Good

Last updated05 Aug 2026

Recent future growth updates

Analysis Article • Feb 15

Analysts Have Been Trimming Their Bruker Corporation (NASDAQ:BRKR) Price Target After Its Latest Report

It's been a sad week for Bruker Corporation ( NASDAQ:BRKR ), who've watched their investment drop 13% to US$36.51 in...

Recent updates

Narrative Update • Aug 07

BRKR: Premium Multiple Will Face Earnings Risk After Recent Guidance Miss

The updated analyst price target for Bruker moves from an implied fair value of about $35.00 to approximately $42.30 as analysts balance slightly higher assumed profit margins and P/E expectations, more cautious revenue growth forecasts, and an unchanged mix of Neutral, Hold, Buy, Overweight and Peer Perform ratings across recent research. Analyst Commentary Recent Street research on Bruker shows a mix of enthusiasm and caution, with several firms adjusting price targets and ratings as they reassess valuation, growth assumptions, and execution risks ahead of earnings updates.
Seeking Alpha • Aug 05

Weak Growth In Its Primary Market Continues To Weigh Heavily On Bruker Shares

Summary Bruker faces ongoing headwinds from weak academic/government funding that has compressed growth despite strong semiconductor and energy research markets. Q2 delivered strong order growth and margin improvement, but revenue missed expectations and near-term guidance is soft, raising execution risk for FY targets. BRKR's high exposure to academic/government end markets remains a structural challenge, but growth in biopharma, diagnostics, and semiconductor segments offers long-term upside. Valuation appears modestly attractive with potential 30%+ upside, yet tepid organic growth and guidance uncertainty temper immediate buy conviction. Read the full article on Seeking Alpha
Narrative Update • Jul 24

BRKR: Infection Detection Expansion Will Meet Rich Tools Sector Expectations

Bruker’s updated analyst price target of $59.75, up from $56, reflects a series of target increases into the $60 to $70 range as analysts recalibrate their models for life science and diagnostic tools stocks and incorporate what they view as reasonable earnings expectations along with improving sentiment toward the group. Analyst Commentary Recent research updates on Bruker show a wide range of price targets clustered between US$60 and US$70, with most analysts adjusting their models for the life science and diagnostic tools sector ahead of upcoming earnings reports.
Narrative Update • Jul 10

BRKR: Diagnostics Portfolio Momentum Will Counter Valuation And Execution Uncertainty

The analyst fair value estimate for Bruker has been raised from $53.25 to $56.00 after analysts responded to a series of higher Street price targets and updated models across diagnostics and life sciences tools coverage. Analyst Commentary Recent Street research on Bruker shows a mix of optimism and caution, with several firms updating price targets and ratings as they refresh models across diagnostics and life sciences tools coverage.
Narrative Update • Jun 26

BRKR: Rich Multiple And Execution Risks Will Pressure Earnings Power Into 2026

Bruker’s analyst fair value estimate has been revised from $36.80 to $35.00 as analysts weigh a richer valuation, even as several recent price target increases in the $60 to $65 range cite updated models and improving sentiment toward life science and diagnostic tools stocks. Analyst Commentary Recent Street commentary on Bruker shows a clear divide between optimistic targets and more cautious views that question how much upside is left at current prices.
Narrative Update • Jun 11

BRKR: Semiconductor And Diagnostics Momentum Will Balance Helium And Execution Risks

The updated analyst price target for Bruker has moved from an implied fair value of $49.15 to $53.25, reflecting recent target hikes into the $65 range by several firms as analysts incorporate refreshed models, sector sentiment, and valuation concerns into their views. Analyst Commentary Recent research updates show a mix of optimism and caution around Bruker, with price targets clustering around US$65 alongside more neutral stances that focus on valuation and operating risks.
Narrative Update • May 28

BRKR: Rising Helium Costs Will Constrain Earnings Power Into 2026

Analysts have lifted their average price target on Bruker by about $1.80, citing updated assumptions that include a slightly lower discount rate, modestly higher revenue growth and profit margin expectations, and a lower future P/E multiple. Analyst Commentary Recent Street research on Bruker reflects a mix of optimism on long term prospects and concern about near term risks.
Narrative Update • May 14

BRKR: 2026 Earnings Delivery Will Outweigh Helium Cost Headwinds

Bruker's updated analyst price target has shifted to $49.15 from $47.86, as analysts factor in moderate adjustments to discount rates, revenue growth, profit margins and expected future P/E multiples, following a mix of recent target raises and cuts across the Street. Analyst Commentary Recent research on Bruker reflects a split view, with some analysts lifting price targets and others trimming them, as they reassess valuation, execution risk and potential headwinds in key input costs.
Narrative Update • Apr 29

BRKR: Helium Cost Pressures And Margin Execution Will Shape 2026 Path

Analysts have trimmed their average price targets on Bruker by several dollars to reflect helium cost headwinds, recent margin pressure and lower valuation multiples, while underlying long term revenue growth and profit margin assumptions remain broadly consistent. Analyst Commentary Bearish analysts have been resetting expectations on Bruker, with several firms cutting price targets by mid single digit to low double digit dollar amounts.
Narrative Update • Apr 15

BRKR: Rising Helium Costs Will Pressure Margins And Test 2026 Earnings

Analysts have reduced their Bruker price targets by mid single digit dollar amounts, citing lower margin expectations, helium related cost headwinds and revised sector multiples. These factors, in turn, feed into a higher implied future P/E and modest adjustments to growth and discount rate assumptions.
Narrative Update • Apr 01

BRKR: 2026 Earnings Framework And Helium Risk Will Shape Future P/E

Bruker's updated analyst price target edges lower to about $48 per share, as analysts trim fair value and future P/E assumptions while factoring in helium cost risks and recent price target resets across the coverage group. Analyst Commentary Recent Street research on Bruker reflects a mix of optimism around long term growth targets and caution around nearer term execution, margins, and input cost risks.
Narrative Update • Mar 18

BRKR: 2026 Earnings Framework And Spatial Biology Expansion Will Support Higher P/E

Analysts have reduced the average Bruker price target to about $48, citing helium cost headwinds, a Q4 margin miss and lower sector valuation multiples, while noting that longer term earnings expectations remain in place. Analyst Commentary Research commentary on Bruker highlights a mix of optimism on long term earnings power and caution around near term execution risks and input costs, particularly helium.
Narrative Update • Mar 03

BRKR: Reset Margins And 2026 Outlook Will Support Higher Forward P/E

Analysts have reset their view on Bruker, trimming the target to about $48 from about $54 as they factor in recent Q4 margin pressure, higher assumed discount rates and lower profit margin expectations. This comes even as revenue growth forecasts and future P/E assumptions move higher and Street research shows a mix of price target cuts and raises across firms.
Narrative Update • Feb 17

BRKR: Future Earnings Reset Will Test 2026 Margin Ramp Assumptions

Analysts have trimmed their fair value estimate for Bruker to $35 from $38, reflecting lower applied multiples on future earnings targets after recent price target cuts across several firms, even as updated assumptions factor in changes to revenue growth and profit margins. Analyst Commentary Recent Street research around Bruker has turned more mixed, with several bearish analysts cutting price targets after the latest quarterly update, even as some firms maintain positive ratings or modestly higher targets.
Analysis Article • Feb 15

Analysts Have Been Trimming Their Bruker Corporation (NASDAQ:BRKR) Price Target After Its Latest Report

It's been a sad week for Bruker Corporation ( NASDAQ:BRKR ), who've watched their investment drop 13% to US$36.51 in...
Narrative Update • Feb 03

BRKR: Q4 Setup And BEST Agreements Will Support Higher Forward P/E Multiple

Analysts have lifted their price targets on Bruker by amounts such as $5, $13 and to $53, citing updated views on the life science tools sector and Q4 setups. This feeds into our slightly higher fair value estimate and revised assumptions for discount rate, revenue growth, profit margin and future P/E.
Narrative Update • Jan 20

BRKR: Constructive Bookings And Rating Upgrade Will Support Higher Forward P E Multiple

Analysts have lifted their Bruker price target to about $54 from about $52, citing slightly higher fair value estimates and modest adjustments to the discount rate, margin assumptions, and future P/E expectations. These changes are supported by a series of recent target hikes and an upgrade to Hold in the life science tools peer group.
Narrative Update • Jan 06

BRKR: Constructive Bookings And Rating Upgrade Will Shape Balanced Forward Expectations

Analysts have raised their price target on Bruker by about US$0.57 to around US$52.36, reflecting updated views that factor in steadier bookings and the recent shift from Sell to Hold in Street ratings. Analyst Commentary Recent Street research on Bruker reflects a more balanced stance, with some analysts turning less negative while still highlighting execution risks and guidance concerns.
Narrative Update • Dec 17

BRKR: Constructive Bookings And Rating Upgrade Will Support Stronger Forward Expectations

Analysts have modestly raised their price target on Bruker to about $52 from roughly $49, citing constructive bookings trends that help offset the impact of a 2025 guidance cut and support a slightly higher long term growth and valuation outlook. Analyst Commentary Analyst reactions to Bruker reflect a balanced mix of optimism and caution, with modest target price increases and a shift in ratings signaling improving sentiment but also recognition of execution and guidance risks.
Narrative Update • Dec 03

BRKR: Constructive Bookings And Rating Upgrades Will Support Stable Forward Expectations

Analysts have modestly increased their price target on Bruker to approximately $49 from about $48, citing constructive bookings despite 2025 guidance cuts and recent upgrades in rating outlook. Analyst Commentary Analyst reactions to Bruker’s updated outlook highlight a more balanced risk and reward profile, with some modest upward revisions to valuation targets despite tempered near term expectations.
Analysis Article • Nov 26

Bruker Corporation's (NASDAQ:BRKR) Shares Bounce 26% But Its Business Still Trails The Industry

Bruker Corporation ( NASDAQ:BRKR ) shares have continued their recent momentum with a 26% gain in the last month alone...
Narrative Update • Nov 19

BRKR: Booking Momentum Will Improve Sentiment Despite Lowered 2025 Outlook

Analysts have modestly increased their price target for Bruker from $40 to $43, citing more constructive bookings and improved financial metrics, even though 2025 guidance has been lowered. Analyst Commentary Recent analyst updates reflect a complex view of Bruker's prospects, with nuanced shifts in expectations tied to the company's latest financial disclosures and forward guidance.
Narrative Update • Nov 03

BRKR: Recent Upgrade Will Drive Confidence In Core Market Resilience

Narrative Update: Bruker Analyst Price Target Increased Analysts have raised Bruker's fair value price target by approximately $1.09 to $47.82, citing improved ratings and updated market assessments, even as growth expectations have moderated slightly. Analyst Commentary Bullish Takeaways Bullish analysts note that the recent price target increase reflects greater confidence in Bruker’s ability to deliver stable financial results in the near term.
Narrative Update • Aug 06

Renewed Biopharma Funding And Cost Savings Will Revitalize Markets

Bruker's consensus analyst price target has declined notably, primarily due to weaker revenue growth forecasts and a lower forward P/E multiple, resulting in a reduced fair value estimate of $46.73. What's in the News Bruker provided guidance for FY2025, projecting revenues of $3.43-$3.50 billion (2%-4% reported growth), driven mainly by M&A (3.5%) and FX tailwind (2.5%), but expects 2%-4% organic revenue decline; Q2 2025 revenue is projected to be approximately flat year-over-year at $795-$798 million (Key Developments).

Earnings and Revenue Growth Forecasts

NasdaqGS:BRKR - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20283,9143003524578
12/31/20273,70222128334912
12/31/20263,557-2113620812
6/30/20263,500-10765190N/A
3/31/20263,459-3622140N/A
12/31/20253,437-2214134N/A
9/30/20253,439-24-1194N/A
6/30/20253,4438049166N/A
3/31/20253,44680175295N/A
12/31/20243,366113136251N/A
9/30/20243,241305157267N/A
6/30/20243,120352168273N/A
3/31/20243,001402181284N/A
12/31/20232,965427243350N/A
9/30/20232,818319206316N/A
6/30/20232,715319201342N/A
3/31/20232,621312149284N/A
12/31/20222,531297145274N/A
9/30/20222,506275119242N/A
6/30/20222,476274114196N/A
3/31/20222,458282176262N/A
12/31/20212,418277190282N/A
9/30/20212,362270254347N/A
6/30/20212,264238312405N/A
3/31/20212,118204304395N/A
12/31/20201,988158235332N/A
9/30/20201,960158169265N/A
6/30/20201,970165140235N/A
3/31/20202,035177N/A234N/A
12/31/20192,073197N/A213N/A
9/30/20192,026207N/A210N/A
6/30/20191,972189N/A185N/A
3/31/20191,925184N/A210N/A
12/31/20181,896180N/A240N/A
9/30/20181,87398N/A211N/A
6/30/20181,84292N/A219N/A
3/31/20181,81384N/A166N/A
12/31/20171,76679N/A154N/A
9/30/20171,706151N/A142N/A
6/30/20171,664161N/A142N/A
3/31/20171,621152N/A177N/A
12/31/20161,611154N/A131N/A
9/30/20161,619146N/A190N/A
6/30/20161,621111N/A208N/A
3/31/20161,646119N/A188N/A
12/31/20151,624102N/A229N/A
9/30/20151,65466N/A149N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BRKR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.7%).

Earnings vs Market: BRKR is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: BRKR is expected to become profitable in the next 3 years.

Revenue vs Market: BRKR's revenue (4.8% per year) is forecast to grow slower than the US market (12.9% per year).

High Growth Revenue: BRKR's revenue (4.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: BRKR's Return on Equity is forecast to be low in 3 years time (16.3%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/10 21:56
End of Day Share Price 2026/08/10 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bruker Corporation is covered by 32 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Luke SergottBarclays
Michael RyskinBofA Global Research
Paul KnightBrean Capital Historical (Janney Montgomery)